Clinical Trials
23 trialsNCT03922100 2026-03-18
Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML
Nerviano Medical Sciences
Phase 1/2 Terminated
NCT05787496 2026-01-28
A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms
NextCure, Inc.
Phase 1 Terminated
NCT04266301 2026-01-13
STIMULUS-MDS2
Novartis
Phase 3 Terminated
NCT03268954 2025-10-29
PANTHER
Takeda
Phase 3 Completed
NCT05209152 2025-07-14
AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome /Chronic Myelomonocytic Leukemia
Amgen
Phase 1 Terminated
NCT05038800 2025-05-21
MK-0482-002
Merck Sharp & Dohme LLC
Phase 1 Terminated
NCT02193958 2025-03-19
Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies
Fujifilm Pharmaceuticals U.S.A., Inc.
Phase 1/2 Completed
NCT02268253 2025-01-06
Tagraxofusp (SL-401) in Participants With Chronic Myelomonocytic Leukemia (CMML) and Myelofibrosis (MF)
Stemline Therapeutics, Inc.
Phase 1/2 Completed
NCT03814005 2024-09-05
A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems
Takeda
Phase 1 Completed
NCT02907359 2024-08-27
Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs
Astex Pharmaceuticals, Inc.
Phase 3 Completed
NCT03306264 2024-08-27
Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML
Astex Pharmaceuticals, Inc.
Phase 3 Completed
NCT02807272 2024-07-17
CMML/AML
Kura Oncology, Inc.
Phase 2 Completed
NCT03175978 2024-05-21
IGF-MTX Conjugate in the Treatment of Myelodysplastic Syndrome
IGF Oncology, LLC
Phase 1/2 Terminated
NCT02367456 2024-01-19
BRIGHT 1012
Pfizer
Phase 1 Completed
NCT04842604 2023-12-18
Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML
Pfizer
Phase 3 Completed
NCT03593915 2023-11-09
A Phase 1b/2 Study of Alvocidib Plus Decitabine or Azacitidine in Patients With MDS
Sumitomo Pharma America, Inc.
Phase 1/2 Terminated
NCT03614728 2023-02-06
Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents to Treat Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
GlaxoSmithKline
Phase 1/2 Terminated
NCT01736683 2022-10-24
Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT02610777 2022-09-19
An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)
Takeda
Phase 2 Completed
NCT00946647 2020-08-04
A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).
Novartis
Phase 1/2 Completed
NCT01957644 2019-02-08
Phase I Dose Escalation Trial of Volasertib in Combination With Azacitidine in Patients With MDS or CMML
Boehringer Ingelheim
Phase 1 Terminated
NCT02201329 2018-07-30
Volasertib in Combination With Azacitidine in Japanese Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Boehringer Ingelheim
Phase 1 Completed
NCT00538850 2014-03-05
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
INSYS Therapeutics Inc
Phase 3 Completed